Bis-choline tetrathiomolybdate

Unassigned

New Medicines

Wilson's disease or hepatolenticular degeneration

Information

New molecular entity
Wilson Therapeutics
Wilson Therapeutics

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Bis-choline tetrathiomolybdate works by binding and chelating copper
A recent epidemiologic study from the UK has suggested an unexpectedly high rate (about 1 in 40) of ATP7B heterozygote mutation carriers, predicting an estimated 1 in 7000 prevalence of Wilson’s disease in the UK population [1].
Wilson's disease or hepatolenticular degeneration
Oral